The company said that its Neumifil lead product candidate and other mCBMs generated with its GlycoTarge platform blocked entry into airway cells for a range of viruses -- including SARS-CoV-2 -- that cause respiratory infections. A spinoff of the University of St. Andrews, Pneumagen said it worked closely with Public Health England's Porton facilities and the University of Glasgow's MRC Centre for Virus Research to test the activity of the mCBMs against coronaviruses using plaque reduction assays.

They found that the mCBMs reduced the number of SARS-CoV-2 plaques in these assays when used in both prevention and treatment of infection.

Valo to develop pancoronavirus vaccine
Valo Therapeutics announced that it is working on the development of a potential COVID-19 vaccine with applications across future pandemics.

What is the impact of aerosolized SARS-CoV-2 in hospitals?
A study evaluating viral RNA from two hospitals in Wuhan, China, during the COVID-19 outbreak reveals that although there are several hotspots for airborne...

CEPI, Clover to partner on COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) and Clover Biopharmaceuticals Australia plan to partner on the development of a COVID-19 vaccine.

AGC Biologics, AdaptVac partner on COVID-19 vaccine
AGC Biologics, a contract development and manufacturing organization, and AdaptVac have teamed up to develop a COVID-19 vaccine.

Nonprofit seeks COVID-19 vaccines for most vulnerable
The nonprofit consortium Human Vaccines Project has launched an initiative to ensure COVID-19 vaccines are developed for vulnerable populations.